Skip to main content

Security report for kyowakirin.com

Kyowa Kirin Co., Ltd. · Healthcare · Japan

Medium risk. 5 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

68/100

Risk levelMedium

0–100, higher is better. How it is calculated

Kyowa Kirin Co., Ltd. is a Japan-based global specialty pharmaceutical company focused on developing innovative specialty drugs, particularly antibody-based therapies for cancer, kidney disease, and immune system diseases. The company maintains a strong international presence with numerous subsidiaries and partner companies across Asia Pacific, North America, and EMEA regions. Their business model centers on research and development, leveraging proprietary technologies and partnerships to address unmet medical needs worldwide. The website reflects a professional and comprehensive corporate presence with rich multimedia content and detailed information about their global operations and corporate philosophy. Technically, the website employs modern web technologies including YouTube embedded videos, Google Tag Manager for analytics, and OneTrust for cookie consent management. The site is mobile-optimized, accessible, and SEO-friendly, though no CMS or hosting provider details are explicitly detected. Performance is moderate with good user experience and navigation clarity. From a security perspective, the site uses HTTPS and has cookie consent mechanisms, but lacks explicit security headers and published security policies or incident response information. No vulnerabilities or exposed sensitive data were detected in the content. The WHOIS data for the domain is missing or unavailable, which is unusual and reduces trust slightly, though the website content and global corporate footprint support legitimacy. Overall, the website scores well on content quality, technical implementation, and business credibility, with moderate privacy compliance and security posture scores. Strategic recommendations include enhancing security headers, publishing security policies, and clarifying domain registration information to improve trust and compliance.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

5 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching kyowakirin.com

This scan found 24 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
67
Security headers
15
Email security
75
DNS health
80
Network security
100
GDPR outside view
68
Average
68

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Kyowa Kirin holds a strong market position as a global specialty pharmaceutical company originating from Japan. Their competitive advantage lies in proprietary antibody technologies and gene therapy pipelines, targeting critical therapeutic areas such as bone and mineral diseases, hematologic malignancies, and rare diseases. The company operates through a network of subsidiaries and partners worldwide, enabling broad market reach and diversified revenue streams. Their business model emphasizes innovation, open partnerships, and patient-centric drug development. The website content and structure indicate a mature organization with a clear vision for 2030 and a commitment to life-changing value creation. Growth indicators include active clinical trials and recent news releases. The partnership ecosystem includes notable entities like FUJIFILM KYOWA KIRIN BIOLOGICS and Orchard Therapeutics, reflecting strategic collaborations in biotechnology and gene therapy.

Security posture

The current security maturity level of the website is moderate. HTTPS is enforced, and cookie consent is implemented, indicating baseline security and privacy awareness. However, the absence of key security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options reduces the overall security posture. No explicit security policy or incident response contact information is published, which may impact incident handling readiness and transparency. There is no evidence of vulnerability disclosure programs or security.txt files. The website does not expose sensitive data or show signs of vulnerable libraries. Overall, the security culture appears basic but could be improved by adopting best practices and enhancing transparency to build stakeholder trust.

Recommendations

  1. Implement comprehensive security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to mitigate common web attacks.
  2. Publish a clear security policy and incident response information on the website to improve transparency and readiness.
  3. Establish a vulnerability disclosure program or security.txt file to encourage responsible reporting of security issues.
  4. Verify and update WHOIS domain registration information to ensure consistency and improve trustworthiness.
  5. Enhance privacy compliance by detailing data retention policies and expanding contact information for data protection inquiries.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Kyowa Kirin Co., Ltd.
Description
The Kyowa Kirin Group is a Japanese pharma group that develops innovative specialty drugs, to raise the health and well-being of people around the world. Its flagship business Kyowa Kirin Co., Ltd. creates antibody-based drugs for cancer, kidney disease, and immune system diseases.
Key services
Development of antibody-based drugs, Gene therapy pipelines, Pharmaceutical product commercialization, Research and development in life sciences
Content quality
excellent
Branding
consistent

Technology

Stack
YouTube iframe API, Google Tag Manager, OneTrust cookie consent, jQuery 3.3.1, Ensighten Tag Management, SyncSearch Suggest
Performance
moderate
Mobile
excellent
Accessibility
good
SEO
good

Security

Observed score
75/100
Good practices seen
  • HTTPS usage implied by canonical and external links
  • Cookie consent mechanism present

Analytics and tracking

Services
Google Analytics (via Google Tag Manager)
Tracking level
moderate
Privacy practices
good

Advertising

Marketing tools
OneTrust Cookie Consent
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content and multimedia
  2. No WAF or blocking mechanisms detected
  3. Comprehensive corporate information and global network details
  4. No direct company emails or phone numbers found in visible content
  5. Privacy and cookie policies are present and comprehensive
  6. No explicit security policy or incident response info published
  7. WHOIS data for domain is missing or not found in .com registry
  8. Use of multiple external trusted domains for subsidiaries and partners
  9. Good SEO and accessibility practices observed
Technical notes

Notes

The website infrastructure utilizes modern web technologies such as asynchronous loading of YouTube iframe API, Google Tag Manager for analytics, and OneTrust for cookie consent management. The presence of jQuery 3.3.1 and custom JavaScript modules indicates a hybrid approach combining legacy and modern scripts. The site is mobile-optimized with responsive design and accessibility features, contributing to a positive user experience. Performance is moderate, with potential for improvement by optimizing script loading and reducing external dependencies. No CMS or hosting provider details are explicitly detected, suggesting a custom or proprietary platform. Technical risks include the lack of security headers and incomplete WHOIS data, which could impact operational security and trust.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with kyowakirin.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review kyowakirin.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.